Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
In hemophilia A, reduced frequency prophylaxis was safe, cut costs
Feldman BM et al. Lancet Haematol. 2018 May 3. doi: 10.1016/S2352-3026(18)30048-6.
Key clinical point:
Major finding: The median CPPES score at the end of the study was 1 (range 0-12) for the left ankle and 1 for the right ankle, with all other joints having a median score of 0.
Study details: Longitudinal design comprising 56 boys with severe hemophilia A who were followed for up to 16.1 years.
Disclosures: The study was initially funded by grants from the Medical Research Council of Canada/Pharmaceutical Manufacturers Association of Canada Partnership Fund and by the Bayer/Canadian Blood Services/Héma-Québec Partnership Fund. Subsequent renewals were funded by Bayer. Dr. Feldman reported grants from Bayer during the conduct of the study and grants from Baxter/Baxalta/Shire outside the submitted work. Several coauthors also report multiple relationships with industry.
Source: Feldman BM et al. Lancet Haematol. 2018 May 3. doi: 10.1016/S2352-3026(18)30048-6.
Feldman BM et al. Lancet Haematol. 2018 May 3. doi: 10.1016/S2352-3026(18)30048-6.